Elite Pharmaceuticals, Inc.
ELTP
$0.37
$0.00-0.62%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 8.61% | 270.71% | 224.16% | -1,055.62% | 411.07% |
| Total Depreciation and Amortization | -5.46% | 3.59% | -7.66% | -9.02% | 3.93% |
| Total Amortization of Deferred Charges | 0.00% | 0.00% | 0.00% | 0.00% | -- |
| Total Other Non-Cash Items | -67.80% | -185.27% | -137.01% | 837.05% | -5.31% |
| Change in Net Operating Assets | 70.90% | -451.63% | -70.68% | -654.28% | -511.75% |
| Cash from Operations | 133.45% | -396.23% | 250.38% | 369.89% | 86.62% |
| Capital Expenditure | 47.22% | -- | -11.80% | 71.97% | -86.84% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 47.22% | -- | -686.93% | 86.88% | -86.84% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 23.16% | 35.89% | 16.90% | -2,261.75% | 61.02% |
| Issuance of Common Stock | 306.74% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 69.71% | 82.60% | 63.67% | -2,261.75% | 65.84% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 187.65% | -339.06% | 323.38% | 698.21% | 133.76% |